ClinicalTrials.gg
RecruitingNCT05327647BicaBCaUpdated Oct 26, 2026

A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer

A Phase 2 interventional study of Bicalutamide and Control Arm in Non-Muscle Invasive Bladder Cancer, sponsored by CHU de Quebec-Universite Laval. Recruiting at 7 sites in Canada. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by CHU de Quebec-Universite Laval · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2022; still recruiting 4 years 4 months later.
Updated Oct 26, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Non-Muscle Invasive Bladder Neoplasms with a site in Canada — 10 open to participants now, 15 under way, 6 of them phase 3. Non-Muscle Invasive Bladder Neoplasms · Canada.

Planned enrollment
11th of 24
160 · median 138
Started
2022
with 1 other
Phase 2
7 of 26
4 open now
Primary completion
2027-05
later than 4 of 14 live
Registered
17th of 26
by date
Lead sponsor
1 of 26
CHU de Quebec-Universite Laval

Among the 26 studies in Non-Muscle Invasive Bladder Neoplasms with a site in Canada, this one is the 11th largest by planned enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2022, is one of 7 in phase 2, reaches primary completion later than 4 of the 14 other live ones, and was the 17th registered.

Non-Muscle Invasive Bladder Neoplasms

295 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 127 are open to participants now.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Open to participants now

10 of the 26 studies in Non-Muscle Invasive Bladder Neoplasms with a site in Canada are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 93 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 78 (84%) set no upper age limit and 5 (5%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Non-Muscle Invasive Bladder Neoplasms with a site in Canada, or all of them as a file.
02

Study summary

This is a phase II randomized controlled clinical trial comparing standard induction BCG versus bicalutamide and standard induction BCG among patients with non-muscle invasive bladder cancer.

Read the detailed description

Bladder cancer is the second most common urological cancer after prostate cancer. Non-muscle invasive bladder cancer (NIMBC) is the most common form (\~ 75%). The standard treatment involves the use of intravesical instillation of bacillus Calmette-Guérin (BCG). Nonetheless, 30-40% of the patients still relapse or progress. Clinical and laboratory research suggests that medications targeting the androgen receptor, such as bicalutamide, combined with the standard treatment with BCG may decrease the recurrence rate of NMIBC.

The study is composed of two cohort A (open-label, around 40 patients) and B (double-blind, with placebo, around 120 patients).

In the cohort A, the participants will be randomized to either the treatment with 1) daily intake of 150 mg bicalutamide for 3 months overlapping with the 6 cycles of intravesical instillations of BCG or 2) the standard of care of 6 cycles of intravesical instillation BCG.

In the cohort B, the participants will be randomized to either the treatment with 1) daily intake of 150 mg bicalutamide for 3 months overlapping with the 6 cycles of intravesical instillations of BCG or 2) daily intake of 150mg placebo for 3 months + the standard of care of 6 cycles of intravesical instillation BCG.

The participation in this trial should last 36 months from the screening visit to the last follow-up visit.

03

Conditions studied

  • Non-Muscle Invasive Bladder Cancer

Keywords

  • Bicalutamide
  • BCG instillation
  • Placebo
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males, age 18 or greater.
  2. Patients with confirmed non-muscle invasive urothelial carcinoma.
  3. Patients have been recommended for a course of intravesical BCG induction treatment by their urologist
  4. Patients who received gemcitabine, epirubicin or mitomycin C instillations immediately post-operatively will be eligible for enrollment.
  5. Patients with partners of must agree to 2 acceptable forms of and be continued for at least 3 months after study drug is discontinued.

Exclusion criteria

Exclusion Criteria:

  1. Patients who have received induction BCG therapy within the last 5 years will be ineligible for enrolment.
  2. Patients with a history of myocardial infarction or hospital admission for heart failure within the previous 12 months or who have unstable cardiovascular status will be ineligible for enrolment.
  3. Patients who have uncontrolled hypertension (for our purposes, defined as those having a systolic blood pressure > 160 documented on 2 occasions despite appropriate medical therapy) will similarly be ineligible.
  4. Patients with a history of liver disease whose hepatic enzymes, alkaline phosphatase or are greater than twice the will be ineligible.
  5. Patients with clinical hypogonadism, those on androgen replacement therapy, or those with prostate cancer or other diseases treated with systemic hormonal therapy will be ineligible for study enrolment. Patients receiving 5ARIs will not be excluded.
  6. Patients who have cancer treatment ongoing or planned in the near future which can be anticipated to decrease their 2-year survival or BCa treatment plan will be ineligible.
  7. Patients taking an drug within 2 weeks of enrolment into this study will be ineligible.
  8. Patients receiving or planning to receive coumadin therapy will be ineligible.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
Single (Participant)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Bicalutamide

    Induction intravesical Bacille Calmette-Guérin treatment with 150 mg daily oral bicalutamide for 90 days (in cohort A and cohort B)

    Drug: Bicalutamide

  • Active comparator
    Control Arm

    cohort A: Induction intravesical Bacille Calmette-Guérin treatment cohort B: Induction intravesical Bacille Calmette-Guérin treatment with 150 mg daily oral placebo for 90 days

    Biological: Control Arm

Interventions

  • Induction intravesical BCG with bicalutamide 150 mg for 90 days

    Also known as: Nonsteroidal antiandrogen

  • BiologicalControl Arm

    Induction BCG

06

What researchers measure

Primary outcomes

  1. Rate of bladder tumour recurrence

    To time to bladder tumor recurrence compared to the standard of care induction BCG

    Time frame: 3 years

Secondary outcomes

  1. Incidence of tumour progression

    To compare the incidence of tumor progression between the intervention and control arms

    Time frame: 3 years

  2. Number of tumor recurrences

    To compare the overall incidence of tumor recurrences between intervention and control arms

    Time frame: 3 years

  3. Number of tumours at first recurrence

    Evaluation of the number of tumours at first recurrence between the two arms

    Time frame: 3 years

  4. Quality of life (QLQ-C30)

    Evaluation of quality of life with QLQ-C30 questionnaire (EORTC Core Quality of Life questionnaire). The scale scores range from 0 to 100. A high score for a functional scale represents a high level of functioning, whereas a high score for a symptom scale/single item represents a high level of symptom

    Time frame: 3 years

  5. Evaluation of urinary symptoms

    Evaluation of urinary symptoms with International Prostate Symptom Score (IPSS) . questionnaire. The total score can range from 0 to 35 (0 being asymptomatic and 35 being very symptomatic).

    Time frame: 3 years

07

Study locations

7 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jun 2022 (actual). Primary completion is estimated for May 2027, 58 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Sep 2026 → May 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2022
First posted
Apr 14, 2022
StartActual
Jun 23, 2022
Primary completionEst.
May 1, 2027was Sep 2026
CompletionEst.
Dec 31, 2027was Dec 2026
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 1, 2026→May 1, 2027
Oct 26, 2026
Study completion
Dec 31, 2026→Dec 31, 2027
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Primary completion Sep 1, 2026→May 1, 2027
    Study completion Dec 31, 2026→Dec 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05327647
Collaborators
Canadian Institutes of Health Research (CIHR), Cancer Research Society
Responsible party
Sponsor
First posted
Apr 14, 2022
Start date
Jun 23, 2022
Primary completion
May 1, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 26, 2026

Study contacts

Paul Toren, MD,PhD,FRCSC
Contact
paul.toren@crchudequebec.ulaval.ca
418-525-4444 ext. 17064
Paul Toren, MD,PhD,FRCSC
study chair · CHU de Québec-Université Laval
Wassim Kassouf, MDCM,FRCSC
principal investigator · McGill University Health Centre/Research Institute of the McGill University Health Centre
Melissa Huynh, MD,MPH,FRCSC
principal investigator · London Health Sciences Centre, Victoria Hospital
Jean-Baptiste Lattouf, MD,FRCSC
principal investigator · Centre Hospitalier Universitaire de Montréal (CHUM)
Girish Kulkarni, BSc, MD, PhD, FRCSC
principal investigator · The Princess Margaret Cancer Foundation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bicalutamide

Start the discussion